Skip Navigation

Annals of Oncology 2006 17(Supplement 5):v113-v117; doi:10.1093/annonc/mdj964
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bellmunt, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellmunt, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium

J. Bellmunt*, S. Albiol, A. Ramírez de Olano, J. Pujadas, P. Maroto On behalf the Spanish Oncology Genitourinary Group (SOGUG)

Medical Oncology Service, Hospital General Universitari Vall d'Hebron, Barcelona, Spain

* Correspondence to: Dr J. Bellmunt, Medical Oncology Service, Hospital General Universitari Vall d'Hebron. P. Vall d'Hebron 119–129. 08035 Barcelona, Spain. Tel: +34-93-2746085; Fax: +34-93-2746059; E-mail: jbellmunt{at}ecodi.net, jbellmunt{at}vhebron.net

M-VAC (cisplatin, methotrexate, adriamycin, vinblastine) combination chemotherapy has been for long time the standard of care in fit patient with advanced urothelial tumors. Gemcitabine/cisplatin with similar results and an improved toxicity profile has proved to be a new standard alternative. Whether or not we can improve survival with newer triplet regimens will depend upon the results of ongoing phase III trials. In addition to the new active drug combinations and targeted therapies, new approaches are emerging for treatment. Chemotherapy optimization using molecular markers predicting chemosensitivity are being applied. There is an obvious need to incorporate in clinical trials a systematic translational approach to explain both our successes and our failures.

Key words: bladder cancer, chemotherapy, gemcitabine, urothelial cell cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.